YP4

N-[(1R)-1-(naphthalen-1-yl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine

Find entries where: YP4

is present as a standalone ligand in 6 entries

Find related ligands:

Chemical Component Summary
Name	N-[(1R)-1-(naphthalen-1-yl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine
Identifiers	~{N}-[(1~{R})-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine
Formula	C₂₂ H₂₂ F₃ N
Molecular Weight	357.412
Type	NON-POLYMER
Isomeric SMILES	C[C@H](c1cccc2c1cccc2)NCCCc3cccc(c3)C(F)(F)F
InChI	InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1
InChIKey	VDHAWDNDOKGFTD-MRXNPFEDSA-N

Chemical Details
Formal Charge	0
Atom Count	48
Chiral Atom Count	1
Bond Count	50
Aromatic Bond Count	17

Drug Info: DrugBank

DrugBank ID	DB01012
Name	Cinacalcet
Groups	approved
Description	Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
Synonyms	N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine Cinacalcet Cinacalcet hydrochloride CNC (R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
Brand Names	Priva-cinacalcet Auro-cinacalcet PMS-cinacalcet Jamp Cinacalcet Jamp Cinacalcet Tablets Mylan-cinacalcet Mimpara Mar-cinacalcet Teva-cinacalcet Apo-cinacalcet Cinacalcet Accordpharma Cinacalcet Mylan M-cinacalcet Reddy-cinacalcet Sensipar Cinacalcet Hydrochloride Cinacalcet Sandoz Cinacalcet
Indication	For the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease who are on hemodialysis or peritoneal dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma.
Categories	Anti-Parathyroid Agents Calcimimetic Agents Calcium Homeostasis Calcium-Regulating Hormones and Agents Calcium-sensing Receptor Agonist Cytochrome P-450 CYP1A2 Substrates Cytochrome P-450 CYP2D6 Inhibitors Cytochrome P-450 CYP2D6 Inhibitors (strong) Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Substrates Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Increased Calcium-sensing Receptor Sensitivity Naphthalenes Other Miscellaneous Therapeutic Agents Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins
ATC-Code	H05BX01
CAS number	226256-56-0

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Extracellular calcium-sensing receptor	MAFYSCCWVLLALTWHTSAYGPDQRAQKKGDIILGGLFPIHFGVAAKDQD...	unknown	agonist
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	substrate
Cytochrome P450 2D6	MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVD...	unknown	inhibitor
Cytochrome P450 1A2	MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL...	unknown	substrate

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682